培美曲塞联合顺铂治疗晚期非小细胞肺癌患者的疗效观察

Efficacy of pemetrexed plus cisplatin in treating advanced non small cell lung cancer

目的探讨培美曲塞联合顺铂与吉西他滨联合顺铂两种治疗方案治疗晚期非小细胞肺癌(NSCLC)患者的疗效及对肿瘤标志物水平的影响。方法选取2013年5月至2016年7月间上海市第六人民医院收治的128例NSCLC患者,根据治疗方法将入选患者分为观察组与对照组,每组64例。观察组患者采用培美曲塞联合顺铂进行治疗,对照组患者采用吉西他滨联合顺铂进行治疗。比较两组患者的治疗总有效率、临床症状改善情况及治疗前后肿瘤标志物水平变化情况。结果观察组患者治疗总有效率为96.9%,显著高于对照组患者的79.7%。两组比较,差异有统计学意义(P<0.01)。观察组患者咳嗽、咳痰、发热、胸痛、乏力和气促的发生率均低于对照组患者,差异均有统计学意义(均P<0.05)。治疗后观察组患者的肿瘤标记物均显著低于对照组患者,差异均有统计学意义(均P<0.05)。结论培美曲塞联合顺铂治疗晚期NSCLC患者疗效较为显著,改善了肿瘤标志物水平,值得推广。

Objective To analyze the clinical efficacy of pemetrexed plus cisplatin versus gemcitabine plus cisplatin in treating the patients with non small cell lung cancer（ NSCLC） and the influence on the levels of tumor markers. Methods Clinical data of 128 NSCLC patients with treated at Shanghai Sixth People＇s Hospital from May 2013 to July 2016 was selected. According to the therapeutic regimen,patients were divided into an observation group and a control group with 64 patients in each group. Patients in the observation group received pemetrexed plus cisplatin patients in the control group received gemcitabine plus cisplatin. Overall treatment effectiveness,improvement of the clinical symptoms and changes of tumor marker levels before and after treatment were compared between the two groups. Results The overall treatment effectiveness was obviously higher in the observation group（ 96. 9%） than in the control group（ 79. 7%）（ P 0. 01）. The incidence rate of cough,expectoration,heat,chest pain,fatigue and shortness of breath was obviously lower in the observation group than in the control group（ P 0. 05）. There was no statistical difference in tumor marker levels between the two groups before the treatment（ P 0. 05）. The levels of tumor markers was obviously lower in the observation group than in the control group after treatment（ P 0. 05）. Conclusion The efficacy of pemetrexed plus cisplatin in treating NSCLC is obvious,which plays an important role in decreasing the levels of tumor markers. It＇s worth promoting.